Scrip100: Indian firms up R&D spend, ascend value chain
This article was originally published in Scrip
Executive Summary
The R&D spends of a clutch of frontline Indian firms have seen a significant uptick over the past few years, seemingly in line with their growing emphasis on complex therapy and limited competition areas as well as the efforts of some to make a mark in the biosimilars space.